History of smallpox vaccination and marked clinical expression of mpox among cases notified in France, from May to July 2022
Catarina Krug,Emilie Chazelle,Arnaud Tarantola,Harold Noël,Guillaume Spaccaferri,Isabelle Parent du Châtelet,Laura Zanetti,Hana Lahbib,Myriam Fayad,Florence Lot,Henriette De Valk,Didier Che,Bruno Coignard,Alexandra Mailles,Anne-Sophie Barret,Investigation Team,lazare Agbahoungba,Amina Ahamadi,Ulviyya Alizada,Laetitia Ali-Oicheih,Catherine Aventini,Patrick Baguet,Elsa Balleydier,Marie Barba-Vasseur,Catherine Bec,Leila Beikheira,Anne Bernadou,Julien Berra,Nathalie Bonnet,Elise Brottet,Patrick Calen,Chappert Jean-Loup,Victorien Dachary,Carole Dagorne,Sander De Souza,Brigitte Demma,Audrey Diavolo,Florence Didier,Frédérique Dorleans,Jacques El Kouri,Céline Erieau,Erica Fougere,Sabrina Fournier,Diane François,Olivier Glass,Sophie Grellet,Axel Grellier,Carine Grenier,Anne Guinard,Guyonnet Jean-Paul,Valerie Henry,Robin Le Barreau,Anne Laporte,Clara Leyendecker,Florence Lot,Marion Louault,Louise Luan,Yoann Mallet,Laurence Marais,Nathalie Mathevet,Christine Meffre,Abdoul Djamal Moukaila,Ronan Ollivier,Damien Ott,Christine Pere,Laure Petit-Made,Valérie Pontiès,Philippe Reboud,Laura Reques,Patrick Rolland,Asma Saidouni Oulebsir,Lucie Sautron,Yassoungo Silue,Yvan Souares,Ndeye Fatou Sow,Ami Yamada,Gabriel Yubero,Aurélien Zhu-Soubise
DOI: https://doi.org/10.1016/j.cmi.2024.03.038
IF: 13.31
2024-04-09
Clinical Microbiology and Infection
Abstract:Objectives The aim was to estimate the effect of reported history of smallpox vaccination prior to 1980 on clinical expression of mpox. Methods We included all confirmed mpox cases identified by the national mpox surveillance system in France between May and July 2022. Cases tested positive for monkeypox virus or orthopoxviruses by PCR. Cases were interviewed by phone using a questionnaire documenting demographics, symptoms and exposures. To estimate the effect of smallpox vaccination on presence of marked mpox symptoms (association of fever, lymphadenopathy and extensive mucocutaneous lesions), we estimated prevalence ratios (PR) and 95% confidence intervals (CI) using Poisson regression models with robust standard errors. Results There were 1,888 confirmed mpox cases with date of symptom onset between 7 May and 31 July 2022. Overall, 7% (93/1,394) presented marked mpox symptoms. Among cases who provided information about their vaccination status, 14% (207/1,469) reported smallpox vaccination prior to 1980. The proportion of cases with marked symptoms was 2% (3/170) among those reporting smallpox vaccination prior to 1980 and 8% (76/974) among those who reported no vaccination. The proportion of marked symptoms was four times lower among cases reporting previous smallpox vaccination than in cases reporting no vaccination (PR 0.24, 95%CI: 0.08-0.76). There was no evidence of an effect of smallpox vaccination on development of complications (PR 0.65, 95%CI: 0.35-1.22) or hospitalisation due to mpox (PR 0.64, 95%CI: 0.23-1.80). Conclusions Our results suggest that smallpox vaccination during childhood attenuated the clinical expression of monkeypox virus infection, but there was no evidence of an effect on complications or hospitalisation.
infectious diseases,microbiology